Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 50.928
Filtrar
1.
Brasília, D.F.; OPAS; 2020-11-05. (OPAS-W/BRA/PHE/COVID-19/20-141).
No convencional en Portugués | PAHO-IRIS | ID: phr2-52984

RESUMEN

O Grupo Consultivo Estratégico de Especialistas em Imunização (SAGE) é o principal grupo consultivo da OMS para vacinas e imunização. Os Grupos de Trabalho do SAGE são estabelecidos como recursos destinados a aumentar a efetividade das deliberações do SAGE. Os Grupos de Trabalho do SAGE ponderam as recomendações para normas sobre vacinas com base na qualidade das evidências, conforme descrito em sua estrutura de Evidências para Recomendação. Em junho de 2020, o SAGE estabeleceu um Grupo de Trabalho para vacinas contra a COVID-19. O Grupo de Trabalho fornecerá informações baseadas em evidências e opções de recomendações para discussão por todo o SAGE em um fórum aberto. Esse Grupo de Trabalho será solicitado a ajudar o SAGE a aconselhar a OMS e seus Estados Membros sobre o uso acelerado de vacinas (pré-licenciamento e pós-licenciamento) para mitigar o impacto da COVID-19 na saúde pública, para possivelmente reduzir a pandemia em curso, bem como para prevenir ou reduzir o risco de propagação de doenças no futuro. A oportunidade de comunicar as necessidades de dados para a tomada de decisões sobre normas garantirá uma abordagem coordenada com a comunidade de pesquisa e desenvolvimento (P&D) de vacinas, a fim de acelerar os prazos e maximizar os esforços globais na tomada de decisões sobre normas baseadas em evidências para o melhor uso de vacinas contra COVID-19.


Asunto(s)
Infecciones por Coronavirus , Coronavirus , Infecciones por Coronavirus , Inmunización , Urgencias Médicas , Epidemias , Pandemias , Vacunas
2.
Brasília, D.F.; OPAS; 2020-11-05. (OPAS-W/BRA/PHE/COVID-19/20-138).
No convencional en Portugués | PAHO-IRIS | ID: phr2-52983

RESUMEN

Como parte de seu escopo no cenário de grupos de modelagem e iniciativas relacionadas a vacinas contra a COVID-19, convidamos modeladores e economistas a fornecer informações sobre o trabalho na vacinação contra a COVID-19 que abordem perguntas de modelagem priorizadas de modo a contribuir para orientar as deliberações sobre as recomendações para normas do SAGE OMS para imunizações. Os grupos são encorajados a compartilhar o estágio inicial e os resultados provisórios de qualquer uma das perguntas como parte do processo contínuo de análise de evidências, identificação de lacunas e refinamento de perguntas e contextos prioritários.


Asunto(s)
Infecciones por Coronavirus , Coronavirus , Infecciones por Coronavirus , Vacunas , Enfermedades Transmisibles , Inmunización
3.
Washington, D.C.; OPS; 2020-11-16. (OPS/FPL/IM/COVID-19/20-0020).
No convencional en Francés | PAHO-IRIS | ID: phr-53018

RESUMEN

La réunion visait à communiquer aux membres du GCT les informations les plus récentes sur la situation épidémiologique de la COVID-19 dans les Amériques, sur ses répercussions à ce jour relativement aux programmes de vaccination et sur les mesures prises par l’OPS pour garantir que les services de vaccination soient maintenus dans toute la Région en tant que services de santé essentiels. Une mise à jour a par ailleurs été faite quant aux efforts de l’OPS pour faciliter l’accès équitable des pays de la Région aux vaccins contre la COVID-19 et la préparation de leur introduction.


Asunto(s)
Infecciones por Coronavirus , Coronavirus , Infecciones por Coronavirus , Enfermedades Prevenibles por Vacunación , Inmunización , Determinantes Sociales de la Salud , Factores de Riesgo
4.
Washington, D.C.; OPAS; 2020-11-16. (OPAS/FPL/IM/COVID-19/20-0020).
No convencional en Portugués | PAHO-IRIS | ID: phr-53016

RESUMEN

A reunião teve o propósito de informar os membros do GTA sobre a atual situação epidemiológica da COVID-19 na Região das Américas, o impacto da pandemia nos programas de vacinação até o momento e as ações tomadas pela OPAS para assegurar a continuidade dos serviços de vacinação em toda a Região como serviços de saúde essenciais. Os participantes da reunião tomaram ciência dos esforços da OPAS para facilitar aos países da Região o acesso equitativo às vacinas contra a COVID-19 e para preparação para introduzir a vacina.


Asunto(s)
Infecciones por Coronavirus , Coronavirus , Infecciones por Coronavirus , Enfermedades Prevenibles por Vacunación , Determinantes Sociales de la Salud , Inmunización
5.
Washington, D.C.; OPS; 2020-11-16. (OPS/FPL/IM/COVID-19/20-0020).
No convencional en Español | PAHO-IRIS | ID: phr-53015

RESUMEN

La finalidad de la reunión fue actualizar a los miembros del GTA sobre la situación epidemiológica de la COVID-19 en la Región de las Américas, su repercusión sobre los programas de inmunización hasta la fecha y las medidas adoptadas por la OPS para asegurar que los servicios de vacunación en toda la Región se mantengan como servicios de salud esenciales. Por otro lado, se presentó una actualización sobre las medidas tomadas por la OPS para facilitar el acceso equitativo de los países de la Región a las vacunas contra la COVID-19 y su preparación para la introducción de la vacuna.


Asunto(s)
Infecciones por Coronavirus , Coronavirus , Infecciones por Coronavirus , Enfermedades Prevenibles por Vacunación , Inmunización , Determinantes Sociales de la Salud
6.
Washington, D.C.; OPS; 2020-11-11.
en Español | PAHO-IRIS | ID: phr-53014

RESUMEN

Las vacunas salvan entre 2 y 3 millones de vidas cada año y protegen a toda la población contra más de una docena de enfermedades potencialmente mortales. Gracias a la vacunación se erradicó la viruela en el año 1980 y estamos en vías de erradicar la poliomielitis. No obstante, en los últimos años ha habido un aumento en los casos de sarampión, una de las enfermedades conocidas más contagiosas. Por esta razón es necesario alcanzar una cobertura de vacunación de 95% o más, lo que constituye un gran desafío técnico y de comunicación para el personal de salud. Los estudios demuestran que informar sobre la calidad, la seguridad, la eficacia y la oferta de las vacunas no es suficiente para lograr cambios de conducta frente a la vacunación y que, en general, no aumenta su cobertura. Por este motivo, es necesario comprender las razones que llevan a las personas a no vacunarse o a no vacunar a sus hijos, con vistas a iniciar un diálogo bidireccional basado en el respeto que redunde en mensajes mejores y más eficaces. En este contexto, las presentes orientaciones tienen como objetivo principal facilitar a los equipos de salud herramientas que sirvan de apoyo para la comunicación efectiva entre el personal de salud y la población general, con miras a lograr el objetivo de fortalecer, mantener o recuperar la confianza en las vacunas y en los programas de inmunización en la Región de las Américas.


Asunto(s)
Inmunización , Vacunas , Vacunación , Cuidadores , Familia , Infecciones por Coronavirus , Coronavirus , Infecciones por Coronavirus , Vacuna Tetravalente Recombinante contra el Virus del Papiloma Humano Tipos 6, 11 , 16, 18 , Papiloma , Sarampión , Vacunas contra la Influenza , Virus de la Influenza A , Virus de la Influenza B , Influenzavirus C , Vacuna contra el Sarampión-Parotiditis-Rubéola
7.
Saudi Med J ; 41(11): 1197-1203, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-33130839

RESUMEN

OBJECTIVES: To investigate whether the coronavirus disease-2019 pandemic has had any effects on pediatric vaccination rates at the main university hospital in Saudi Arabia. METHODS: A retrospective study conducted at King Saud University Medical City, Riyadh, Saudi Arabia using electronic health records. The vaccination statuses of all children who were scheduled for vaccinations at birth and at 2, 4, 6, 9, and 12 months during March, April and May between 2017 and 2020 were included in the study with total sample of 15,870 children, and comparisons between the cohorts were performed. RESULTS: All vaccination visits during April and May 2020 were below the lower extremes except for the birth vaccinations. In March, April, and May 2020 there were respective drops in vaccination visits of 49.93%, 71.90% and 68.48% compared with the mean numbers of vaccination visits during the same months from 2017 to 2019. In comparisons of mean numbers of visits from March 2017 to May 2019 and March to May in 2020, the respective reductions in visits for birth and 2, 4, 6, 9 and 12-month vaccinations were 16.5%, 80.5%, 74.7%, 72.9%, 80.0% and 74.1%. CONCLUSIONS: The huge impact of the coronavirus disease-2019 pandemic on childhood vaccinations will require urgent vaccination recovery plans with innovative approaches and future action plans to maintain vaccination coverage during any subsequent pandemics.


Asunto(s)
Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/prevención & control , Inmunización/estadística & datos numéricos , Pandemias/prevención & control , Neumonía Viral/epidemiología , Neumonía Viral/prevención & control , Cobertura de Vacunación/estadística & datos numéricos , Factores de Edad , Preescolar , Estudios de Cohortes , Femenino , Hospitales Universitarios , Humanos , Inmunización/métodos , Incidencia , Lactante , Recién Nacido , Masculino , Pandemias/estadística & datos numéricos , Estudios Retrospectivos , Arabia Saudita/epidemiología , Factores Sexuales
8.
Recurso de Internet en Portugués | LIS - Localizador de Información en Salud | ID: lis-47926

RESUMEN

A Sociedade Brasileira de Pediatria (SBP), a Sociedade Brasileira de Imunizações (SBIm) e a Federação Brasileira de Ginecologia e Obstetrícia (Febrasgo) divulgaram o documento técnico “Imunização na gestação: pré-concepção e puerpério” com o objetivo de orientar profissionais de saúde sobre a importância da vacinação durante a gestação.


Asunto(s)
Periodo Posparto , Embarazo/inmunología , Inmunización , Atención Preconceptiva
9.
Artículo en Francés | PAHO-IRIS | ID: phr-52958

RESUMEN

Dans Ce Numéro: Mise au point, distribution et approvisionnement des vaccins | Ce que j’ai appris en tant que conseiller en vaccination pendant la pandémie de COVID-19... par Marc Rondy, point focal de l’OPS/OMS en vaccination au Guatemala | Programmes nationaux de vaccination pendant la pandémie de COVID-19 : situation au mois | Lignes directrices visant la planification du lancement du vaccin contre la COVID-19


Asunto(s)
Infecciones por Coronavirus , Coronavirus , Infecciones por Coronavirus , Pandemias , Programas de Inmunización , Inmunización , Vacunación , Américas , Región del Caribe , Guatemala
10.
Artículo en Portugués | PAHO-IRIS | ID: phr-52957

RESUMEN

Nesta Edição: Desenvolvimento, distribuição e fornecimento de vacinas | Lo que aprendi como assessor de imunização durante a pandemia de COVID-19… Marc Rondy, ponto focal para imunização da OPAS/OMS na Guatemala | Resumo da situação dos programas nacionais de imunização durante a pandemia de COVID-19 | Orientações para o planejamento da introdução da vacina contra a COVID-19


Asunto(s)
Infecciones por Coronavirus , Coronavirus , Infecciones por Coronavirus , Inmunización , Programas de Inmunización , Vacunación , Pandemias , Américas , Región del Caribe , Guatemala
11.
Artículo en Español | PAHO-IRIS | ID: phr-52956

RESUMEN

En esta edición: Desarrollo, distribución y suministro de vacunas | Lo que aprendí como asesor de inmunización durante la pandemia de COVID-19… Marc Rondy, Punto Focal de Vigilancia para COVID-19 de la OPS/OMS en Guatemala | Resumen de la situación de los programas nacionales de inmunización durante la pandemia de COVID-19 | Orientaciones para la planificación de la introducción de la vacuna contra la COVID-19


Asunto(s)
Programas de Inmunización , Inmunización , Vacunas , Vacunación , Américas , Región del Caribe , Infecciones por Coronavirus , Guatemala , Pandemias , Coronavirus , Infecciones por Coronavirus
12.
Artículo en Inglés | PAHO-IRIS | ID: phr-52953

RESUMEN

In this edition: Vaccine Development, Distribution, and Supply | What I Have Learned as an Immunization Advisor during the COVID-19 Pandemic… | Summary of The Status of National Immunization Programs During the Covid-19 Pandemic | Guidelines to Plan for COVID-19 Vaccine Introduction


Asunto(s)
Inmunización , Programas de Inmunización , Infecciones por Coronavirus , Pandemias , Vacunas , Vacunación , Coronavirus , Infecciones por Coronavirus , Américas , Región del Caribe , Guatemala
13.
Lima; Perú. Ministerio de Salud; 20201000. 37 p. tab.
Monografía en Español | LILACS, MINSAPERÚ | ID: biblio-1123158

RESUMEN

El documento contiene la estrategia para la implementación de la vacunación segura como medida de prevención contra la COVID-19 en el país.


Asunto(s)
Vacunación Masiva , Inmunización , Vacunación , Infecciones por Coronavirus
14.
Emerg Microbes Infect ; 9(1): 2361-2367, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-33118859

RESUMEN

The coronavirus disease 2019 (COVID-19) pandemic is still ongoing and has become an important public health threat. This disease is caused by a new coronavirus named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, and so far, little is known about this virus. In this study, by using plaque purification, we purified two SARS-CoV-2 virus strains from the same specimen, one named F8 containing a 12-bp deletion in the E gene and the other named 8X containing the wild-type E gene. There was no significant difference in the viral titer and infectivity of these two strains. The S protein content of the F8 viral culture was 0.39 µg/ml, much higher than that of 8X. An inactivated vaccine made from the F8 strain could trigger high levels of the IgG titer and neutralizing antibody titer, which could last for at least 6 weeks and were significantly higher than those from the 8X strain at 1 and 3 weeks post vaccination, respectively. In conclusion, we reported that both the E gene mutant and wild-type SARS-CoV-2 strains were isolated from the same clinical sample by plaque purification. A 12-bp deletion in the E gene was important for SARS-CoV-2 replication and immunogenicity.


Asunto(s)
Betacoronavirus/genética , Infecciones por Coronavirus/virología , Neumonía Viral/virología , Proteínas del Envoltorio Viral/genética , Animales , Anticuerpos Neutralizantes/inmunología , Anticuerpos Antivirales/inmunología , Betacoronavirus/inmunología , Betacoronavirus/patogenicidad , Infecciones por Coronavirus/epidemiología , Femenino , Humanos , Inmunización , Masculino , Ratones , Ratones Endogámicos BALB C , Pandemias , Neumonía Viral/epidemiología , Eliminación de Secuencia , Glicoproteína de la Espiga del Coronavirus/administración & dosificación , Glicoproteína de la Espiga del Coronavirus/genética , Glicoproteína de la Espiga del Coronavirus/inmunología , Proteínas del Envoltorio Viral/administración & dosificación , Proteínas del Envoltorio Viral/inmunología , Virulencia
15.
Zhonghua Yu Fang Yi Xue Za Zhi ; 54(9): 915-917, 2020 Sep 06.
Artículo en Chino | MEDLINE | ID: mdl-32907278

RESUMEN

Development of an effective vaccine requires a long and complicated process. Preclinical studies and phase Ⅰ, Ⅱ, Ⅲ clinical trials mainly focused on the assessment of the vaccine's safety (tolerability), immunogenicity and efficacy before license. After license, it is necessary to further evaluate the actual effectiveness and safety in the general population through phase Ⅳ clinical trials and optimize the immunization strategies with the disease's epidemiology data. In this special issue, published several articles, which reported the main results of pre-license clinical trials and post-marketing evaluation of various vaccines, it was extremely useful to support vaccine licensing and market use. We encourage the continuous clinical studies and post-marketing evaluation of vaccines, including the novel corona virus-19 vaccines, to provide technical support for the population use, under the situation of COVID-19 pandemic.


Asunto(s)
Ensayos Clínicos como Asunto/organización & administración , Inmunización/métodos , Vacunas , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/prevención & control , Humanos , Pandemias/prevención & control , Neumonía Viral/epidemiología , Neumonía Viral/prevención & control , Vacunas Virales
16.
Zhonghua Yu Fang Yi Xue Za Zhi ; 54(9): 1010-1016, 2020 Sep 06.
Artículo en Chino | MEDLINE | ID: mdl-32907294

RESUMEN

Enterovirus 71 (EV71) is one of the main pathogens of hand, foot and mouth disease (HFMD) and the main pathogen of severe HFMD. In 2015, three EV71 vaccines were successively marketed in China as powerful prevention and control tools for HFMD caused by EV71. To understand the efficacy, immunogenicity, safety and quality stability of the domestic EV71 vaccine after entering into the market and analyze potential problems in its application, this article incorporates research regarding the immune effect, population effect, safety, quality testing and evaluation results, vaccination willingness and vaccination behavior survey to explore the vaccination strategies for the donll stic EV71 vaccine. EV71 vaccine has good immunogenicity, safety, protective efficacy, and good quality stability after entering into the market, however, only a few study focused on its safety when inoculating with other immunization planning vaccines simultaneously. Strengthen safety monitoring and discuss the safety of the EV71 vaccine especially when simultaneously inoculate with other immunization program vaccines are still necessary. Enterovirus evolution and recombination, whilst the probable impact of the EV71 vaccine can be the reason for future changes of HFMD epidemic strains, hence continuous monitoring of antigenic mutations and genetic evolution of enterovirus should be responded to. Encouraging the R&D of polyvalent vaccines against HFMD is also necessary. Parents' lack of HFMD and EV71 vaccine knowledge was common, therefore HFMD knowledge should be strengthened at the same time when introducing the EV71 vaccine to the public. Also, it should be emphasized that the EV71 vaccine can only prevent HFMD caused by EV71.


Asunto(s)
Enterovirus Humano A/inmunología , Enterovirus/inmunología , Enfermedad de Boca, Mano y Pie , Vacunas Virales , China , Humanos , Inmunización , Intención , Mercadotecnía , Vacunación
17.
PLoS Biol ; 18(9): e3000821, 2020 09.
Artículo en Inglés | MEDLINE | ID: mdl-32886672

RESUMEN

As a novel alternative to established surface display or combinatorial chemistry approaches for the discovery of therapeutic peptides, we present a method for the isolation of small, cysteine-rich domains from bovine antibody ultralong complementarity-determining regions (CDRs). We show for the first time that isolated bovine antibody knob domains can function as autonomous entities by binding antigen outside the confines of the antibody scaffold. This yields antibody fragments so small as to be considered peptides, each stabilised by an intricate, bespoke arrangement of disulphide bonds. For drug discovery, cow immunisations harness the immune system to generate knob domains with affinities in the picomolar to low nanomolar range, orders of magnitude higher than unoptimized peptides from naïve library screening. Using this approach, knob domain peptides that tightly bound Complement component C5 were obtained, at scale, using conventional antibody discovery and peptide purification techniques.


Asunto(s)
Anticuerpos/química , Disulfuros/aislamiento & purificación , Dominios de Inmunoglobulinas , Fragmentos de Péptidos/aislamiento & purificación , Dominios y Motivos de Interacción de Proteínas , Animales , Anticuerpos/inmunología , Anticuerpos/metabolismo , Afinidad de Anticuerpos , Formación de Anticuerpos , Especificidad de Anticuerpos , Antígenos/genética , Antígenos/inmunología , Linfocitos B/fisiología , Bovinos , Complemento C5/química , Complemento C5/genética , Complemento C5/inmunología , Regiones Determinantes de Complementariedad/química , Regiones Determinantes de Complementariedad/genética , Regiones Determinantes de Complementariedad/inmunología , Disulfuros/química , Disulfuros/inmunología , Mapeo Epitopo/métodos , Humanos , Inmunización , Dominios de Inmunoglobulinas/genética , Modelos Moleculares , Fragmentos de Péptidos/genética , Fragmentos de Péptidos/inmunología , Dominios y Motivos de Interacción de Proteínas/genética
18.
Br Dent J ; 229(6): 325, 2020 09.
Artículo en Inglés | MEDLINE | ID: mdl-32978554
19.
PLoS One ; 15(9): e0235818, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32915807

RESUMEN

BACKGROUND: Pneumonia is a leading cause of morbidity and mortality among children under five years of age in developing countries, including Ethiopia. However, data on this serious illness among highly susceptible and vulnerable children living in local peri-urban areas are limited. Establishing the prevalence of pneumonia and identifying the associated factors are important for proper planning and intervention. METHODS: A community-based cross-sectional study was conducted among 560 systematically selected children under the age of five years in peri-urban areas of Dessie City from January through March 2019. Data were collected using a pretested structured questionnaire, physical examination of children and direct observation of housing conditions. Pneumonia was examined using World Health Organization (WHO) guidelines as the presence of the symptoms of fast breathing or indrawn chest with or without fast breathing during the two weeks prior to the study. A principal component analysis was used to construct a household wealth index. Data were analyzed using a binary logistic regression model at 95%CI (confidence interval). The analysis involved estimating the crude odds ratio (COR) using bivariate analysis, and adjusted odds ratio (AOR) using multivariable analysis. From the multivariable analysis, variables at p-value of less than 0.05 were declared statistically significant. MAIN FINDINGS: The prevalence of pneumonia among children under five was 17.1% (95%CI: 13.9%-19.9%). Of the participating children, 113 (21.0%) had a cough, 92 (17.1%) had fast breathing, 76 (14.1%) had fever, and 40 (7.4%) of the children had chest indrawn. Domestic fuel was the most common source of cooking fuel 383 (71.1%). Majority 445 (82.6%) of children were fully vaccinated and 94 (17.4%) were not fully vaccinated. Most (481, 89.2%) of the children were got exclusive breastfeeding. Slightly more than half (284, 52.7%) of the under-five children had acute malnutrition and 27.1% of the children had a childhood history of ARI. The multivariable analysis showed using domestic fuel as the energy source for cooking (adjusted odds ratio [AOR] = 3.95, 95%CI: 1.47-10.62), cooking in the living room (AOR = 6.23; 95%CI: 1.80-21.68), overcrowding (AOR = 3.37, 95%CI: 1.56-7.27), child history of acute respiratory infection (ARI) (AOR = 6.12 95%CI: 2.77-13.53), family history of ARI (AOR = 4.69, 95%CI: 1.67-13.12) and acute malnutrition (AOR = 2.43, 95%CI: 1.18-5.04) were significantly associated with childhood pneumonia. CONCLUSION: In this study, pneumonia remains a leading public health problem among under five children in the study area and higher than national averages. Domestic fuel as the energy source for cooking, cooking in the living room, overcrowding, child history of ARI, family history of ARI and acute malnutrition were predictors of pneumonia. Community-based interventions focusing on improving housing conditions, reduced use of domestic biofuels, adequate and balanced food intake, including exclusive breastfeeding of infants, and early treatment of ARIs.


Asunto(s)
Neumonía/epidemiología , Preescolar , Estudios Transversales , Etiopía/etnología , Femenino , Vivienda , Humanos , Inmunización , Lactante , Masculino , Evaluación Nutricional , Neumonía/prevención & control , Salud Pública , Factores de Riesgo , Factores Socioeconómicos
20.
PLoS One ; 15(9): e0235183, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32956421

RESUMEN

Members of the broad complex, tram track, bric-a-brac and zinc finger (BTB-ZF) family of transcription factors, such as BCL-6, ZBTB20, and ZBTB32, regulate antigen-specific B cell differentiation, plasma cell longevity, and the duration of antibody production. We found that ZBTB38, a different member of the BTB-ZF family that binds methylated DNA at CpG motifs, is highly expressed by germinal center B cells and plasma cells. To define the functional role of ZBTB38 in B cell responses, we generated mice conditionally deficient in this transcription factor. Germinal center B cells lacking ZBTB38 dysregulated very few genes relative to wild-type and heterozygous littermate controls. Accordingly, mice with hematopoietic-specific deletion of Zbtb38 showed normal germinal center B cell numbers and antibody responses following immunization with hapten-protein conjugates. Memory B cells from these animals functioned normally in secondary recall responses. Despite expression of ZBTB38 in hematopoietic stem cells, progenitors and mature myeloid and lymphoid lineages were also present in normal numbers in mutant mice. These data demonstrate that ZBTB38 is dispensable for hematopoiesis and antibody responses. These conditional knockout mice may instead be useful in defining the functional importance of ZBTB38 in other cell types and contexts.


Asunto(s)
Formación de Anticuerpos , Linfocitos B/inmunología , Proteínas Represoras/inmunología , Animales , Linfocitos B/citología , Eliminación de Gen , Expresión Génica , Hematopoyesis , Inmunización , Ratones , Ratones Noqueados , Proteínas Represoras/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA